A Kennett1, J Hardy, S Shah, R A'Hern. 1. The Royal Marsden NHS Foundation Trust, Sutton, Surrey SM2 5PT, UK. alison.kennett@rmh.nthames.nhs.uk
Abstract
INTRODUCTION: Nausea and vomiting are distressing symptoms affecting between 20% and 70% of patients with advanced cancer. Methotrimeprazine is a phenothiazine antipsychotic used in palliative care for the management of terminal agitation and nausea/vomiting but there is only anecdotal evidence to support its use in palliative care. AIM: To establish whether nausea/vomiting in palliative care patients is improved by the administration of low-dose methotrimeprazine. METHODS: Patients with advanced malignancy were entered at different treatment levels according to symptom severity. The dose was altered according to response (minimum dose 6.25 mg daily po, maximum 25 mg by 24-h subcutaneous infusion). Symptoms and side effects were recorded daily from 0 (baseline) to day 5 using a four-point scale. Any improvement in nausea/vomiting score was taken as a response. RESULTS: Sixty-five patients were entered. The cause of nausea and vomiting was multifactorial in the majority of patients, 35/65 (54%). As expected in a study of patients with poor performance status, the attrition rate was high. Of 53 patients evaluable for response at day 2, 33 (62%) showed some improvement in nausea or vomiting. At day 5, improvement was seen in 20/34 (58%). There was no significant change in "side effects" from baseline with time. CONCLUSION: These results suggest that methotrimeprazine has antiemetic activity.
INTRODUCTION:Nausea and vomiting are distressing symptoms affecting between 20% and 70% of patients with advanced cancer. Methotrimeprazine is a phenothiazine antipsychotic used in palliative care for the management of terminal agitation and nausea/vomiting but there is only anecdotal evidence to support its use in palliative care. AIM: To establish whether nausea/vomiting in palliative care patients is improved by the administration of low-dose methotrimeprazine. METHODS:Patients with advanced malignancy were entered at different treatment levels according to symptom severity. The dose was altered according to response (minimum dose 6.25 mg daily po, maximum 25 mg by 24-h subcutaneous infusion). Symptoms and side effects were recorded daily from 0 (baseline) to day 5 using a four-point scale. Any improvement in nausea/vomiting score was taken as a response. RESULTS: Sixty-five patients were entered. The cause of nausea and vomiting was multifactorial in the majority of patients, 35/65 (54%). As expected in a study of patients with poor performance status, the attrition rate was high. Of 53 patients evaluable for response at day 2, 33 (62%) showed some improvement in nausea or vomiting. At day 5, improvement was seen in 20/34 (58%). There was no significant change in "side effects" from baseline with time. CONCLUSION: These results suggest that methotrimeprazine has antiemetic activity.
Authors: P Critchley; N Plach; M Grantham; D Marshall; A Taniguchi; E Latimer; A R Jadad Journal: J Pain Symptom Manage Date: 2001-08 Impact factor: 3.612
Authors: Paul Glare; Glenn Pereira; Linda J Kristjanson; Martin Stockler; Martin Tattersall Journal: Support Care Cancer Date: 2004-04-24 Impact factor: 3.603
Authors: E Bruera; L Seifert; S Watanabe; N Babul; A Darke; Z Harsanyi; M Suarez-Almazor Journal: J Pain Symptom Manage Date: 1996-03 Impact factor: 3.612
Authors: E D Bruera; T J MacEachern; K A Spachynski; D F LeGatt; R N MacDonald; N Babul; Z Harsanyi; A C Darke Journal: Cancer Date: 1994-12-15 Impact factor: 6.860
Authors: Janet Rea Hardy; Helen Skerman; Jennifer Philip; Phillip Good; David C Currow; Geoffrey Mitchell; Patsy Yates Journal: BMJ Open Date: 2019-09-12 Impact factor: 2.692
Authors: Janet Hardy; Helen Skerman; Paul Glare; Jennifer Philip; Peter Hudson; Geoffrey Mitchell; Peter Martin; Odette Spruyt; David Currow; Patsy Yates Journal: BMC Cancer Date: 2018-05-02 Impact factor: 4.430